10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
69.86
-2.53 (-3.49%)
At close: Oct 16, 2026, 4:00 PM EDT
69.46
-0.40 (-0.57%)
After-hours: Oct 16, 2026, 7:34 PM EDT
10x Genomics Revenue
10x Genomics had revenue of $151.04M in the quarter ending June 30, 2026, a decrease of -12.65%. This brings the company's revenue in the last twelve months to $616.91M, down -4.28% year-over-year. In the year 2025, 10x Genomics had annual revenue of $642.82M with 5.25% growth. That makes 10x Genomics the 10,023rd largest company in the world by revenue and 2,152nd in the United States.
Revenue (ttm)
$616.91M
Revenue Growth
-4.28%
P/S Ratio
14.75
Revenue / Employee
$523,694
Employees
1,178
Market Cap
9.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 642.82M | 32.04M | 5.25% |
| Dec 31, 2024 | 610.79M | -7.94M | -1.28% |
| Dec 31, 2023 | 618.73M | 102.32M | 19.81% |
| Dec 31, 2022 | 516.41M | 25.92M | 5.28% |
| Dec 31, 2021 | 490.49M | 191.65M | 64.13% |
| Dec 31, 2020 | 298.85M | 52.95M | 21.53% |
| Dec 31, 2019 | 245.89M | 99.58M | 68.06% |
| Dec 31, 2018 | 146.31M | 75.23M | 105.83% |
| Dec 31, 2017 | 71.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.51B |
| Smith & Nephew | 6.30B |
| Bruker | 3.50B |
| Globus Medical | 3.14B |
| Insulet | 3.05B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
| Integer Holdings | 1.84B |
TXG News
- 4 days ago - 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026 - PRNewsWire
- 4 days ago - 10x Genomics price target raised to $70 from $47 at TD Cowen - TheFly
- 5 days ago - 10x Genomics price target raised to $70 from $40 at Morgan Stanley - TheFly
- 5 days ago - 10x Genomics price target raised to $100 from $60 at Canaccord - TheFly
- 8 days ago - 10x Genomics price target raised to $80 from $50 at BofA - TheFly
- 10 days ago - 10x Genomics announces research collaboration with Fred Hutchinson - TheFly
- 10 days ago - 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers - PRNewsWire
- 10 days ago - 10x Genomics price target raised to $110 from $52 at Barclays - TheFly